Buprenorphine in the Emergency Department

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal. Primary treatment outcome is attendance at a rapid access addiction medicine clinic within a few days of emergency room presentation. Secondary treatment outcome is treatment status with respect to opioid agonist treatment at one month post emergency room visit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

NCT00032968

Heroin Dependence Morphine Dependence Substance Withdrawal Syndrome

COMPLETED PHASE3

Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal

NCT03489161

Drug Overdose Opioid Withdrawal Opioid-use Disorder

COMPLETED EARLY_PHASE1

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

NCT00032955

Heroin Dependence Morphine Dependence Substance Withdrawal Syndrome

COMPLETED PHASE3

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

NCT04893525

Opioid-use Disorder

RECRUITING PHASE2/PHASE3

Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology

NCT03740243

Opioid-use Disorder

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Withdrawal Opioid-use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Buprenorphine

Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine

Group Type EXPERIMENTAL

Buprenorphine

Intervention Type DRUG

The participant receives buprenorphine

Clonidine

Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine

Group Type ACTIVE_COMPARATOR

Clonidine

Intervention Type DRUG

The participant receives clonidine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buprenorphine

The participant receives buprenorphine

Intervention Type DRUG

Clonidine

The participant receives clonidine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Presenting to the ED in opioid withdrawal or soon to be in withdrawal
2. Minimum age 16
3. English speaking
4. Active phone number
5. Ontario Health Insurance Program card

Exclusion Criteria

1. Pregnant
2. Currently enrolled in a methadone or buprenorphine maintenance
3. Benzodiazepine addiction (or taking \>50mg of valium equivalent/day)
4. Acute hepatitis or liver failure

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No